Opens in a new tab

EOFLOW v Insulet (CFI, 11 April 2025)

Date11 April 2025
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionRevocation Action
Registry referenceACT_56003/2024 · ORD_69191/2024
PartiesEOFLOW Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 11 April 2025 (UPC_CFI_597/2024), the Milan Central Division rules on three issues in EOFLOW’s revocation action against Insulet’s EP 4201327, in which Insulet has counterclaimed for infringement. It refuses further written submissions under Rule 36, holds a late prior art document (US 6,656,159) inadmissible and orders EOFLOW to provide security for costs of EUR 500,000. The order shows how strictly the UPC timetable applies to invalidity attacks and the financial analysis on which security is ordered.

Question

May a revocation claimant rely on new prior art after its statement for revocation, and must it provide security for costs where its financial position has deteriorated?

Decision

The parties having fully argued their positions, further submissions are unnecessary (paragraph 10). US ’159 could have been filed earlier (paragraph 32), it was not in the statement for revocation and did not rebut any argument of the other side, which distinguishes NJOY v VMR Products (paragraphs 33 to 35), Rule 263 concerns amendment of claims, not new evidence on the same claim (paragraph 36). On security, Rule 158 also applies to a revocation claimant, whose role overlaps with that of a defendant in cross-actions (paragraphs 43 to 46). The test is whether there is a legitimate and real concern that costs may not be recoverable (paragraph 49), EOFLOW’s financial indicators are negative and unrebutted (paragraphs 50 to 53). Security is set at 50% of the combined ceilings on recoverable costs in both actions (paragraph 59), to be provided within three weeks (paragraph 60).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 69(4) and 76
Rules of Procedure
Rules 36, 158.1, 263 and 355
Case law cited
Court of Appeal, 17 September 2024, Audi v NST (UPC_CoA_217/2024), Court of Appeal, 29 November 2024, Aarke v SodaStream (UPC_CoA_548/2024), 21 January 2025, NJOY v VMR Products (UPC_CFI_311/2023), Mannheim Local Division, 30 April 2024 (UPC_CFI_218/2023).

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
La division centrale de Milan refuse de nouvelles écritures, écarte comme tardive l’antériorité US 6,656,159 et ordonne à EOFLOW de constituer une garantie de 500 000 euros pour les frais.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.